A comment on 177Lu-PSMA therapy and the LuPIN study data

Posted on October 1st, 2019 by Dr Graham Kelly

177Lu-PSMA-617 (177Lu-PSMA) therapy suddenly has become a big talking point in prostate cancer circles. Delivering radiotherapy via injectable radiopharmaceuticals is being talked up as a coming mega trend in cancer therapy in general, but 177Lu-PSMA and prostate cancer is where the big story lies at the moment.

Read More

An Investment in Biotech: Part 3

Posted on September 10th, 2019 by Graham Kelly


The DARRT Program

The DARRT program aims to use Veyonda® to make radiotherapy more effective . It stands for Direct and Abscopal Response to RadioTherapy.

Read More

An Investment in Biotech: Part 2

Posted on August 23rd, 2019 by Graham Kelly


The IDX backstory (2009-2016). The birth of Noxopharm

Ironically, Noxopharm owes its existence to the failure of the OVATURE study.

Read More

An Investment in Biotech: Part 1

Posted on August 15th, 2019 by Graham Kelly

I have been meaning for some time now to write a general blog about drug development and to put the Veyonda(R)story into that context.

Read More

What you need to know about STING

Posted on July 2nd, 2019 by Dr Graham Kelly

The ‘next big thing’ comes along about every 10-15 years in oncology. The last ‘big things’ were the so-called immuno-oncology drugs (or checkpoint inhibitors) – Yervoy and Opdivo (Bristol-Myers Squibb) and Keytruda (Merck). These drugs were expected to turn cancer therapy on its head based on some early dramatic responses in patients with melanoma and lung cancer, with annual sales of US$100+ billion being projected.

Read More

Recent DARRT-1 interim 6-month data put into context

Posted on May 3rd, 2019 by Dr Graham Kelly
Read More

Comment on interim DARRT-1 data announced February 6, 2019

Posted on February 11th, 2019 by Blog Author

I understand the complexity around the DARRT concept, what we expect to come of the DARRT-1 study, and what the data means that we are reporting on as we move through the study. Boosting the effectiveness of radiotherapy with an immuno-oncology drug is an entirely new area of cancer therapy, so there are no yardsticks to measure us by. The only relevant yardstick is current therapeutic options and whether we can improve on them.

Read More

A Comment on IPO Returns

Posted on October 14th, 2018 by Blog Author

The stock market is on its longest bull run in modern history. The biopharma industry, in particular, is in the longest and most active financing window in its history.

Leerink Partners, a leading U.S.-based investment bank specializing in healthcare, recently published a report on the flow of public equity capital into U.S. biopharma stocks over the past 6 years, having analysed the performance[…]

Read More

Latest Appendix 4C and the CEP program

Posted on July 30th, 2018 by Blog Author

We have been asked if the Company has dropped the CEP program from our list of clinical studies as it wasn’t mentioned in the latest Appendix 4C. The answer is, no, we haven’t. But it is not a priority. We have a busy clinical program using NOX66 in combination with radiotherapy, and we anticipate the […]

Read More

CEO Blog: Timelines and Strategies

Posted on June 11th, 2018 by Blog Author

With NOX66 running in 3 separate clinical programs, there is considerable scope for priorities, commercial strategies, timelines etc to become blurred in shareholders’ minds. Hopefully this will make it clearer. …………………………………………………………………… In terms of priorities: The DARRT program in prostate cancer is #1. We regard this as our primary path to market approval and a […]

Read More

CEO Blog discusses May 9th AFR article on an experimental form of therapy for late-stage prostate cancer

Posted on May 11th, 2018 by Blog Author

An  article appeared in the AFR this week. ‘Billion-dollar molecule’ may extend life in men with prostate cancer – Australian Financial Review, May 9 2018 It concerns a clinical trial being conducted in Australia of a promising experimental form of therapy for late-stage prostate cancer. I have been asked where our efforts with NOX66 in […]

Read More

The Abscopal Response Updated and Reviewed

Posted on March 29th, 2018 by Blog Author

Since Noxopharm’s ASX release last Wednesday about seeing abscopal responses in two patients receiving NOX66, some shareholders have asked me what it means to the future treatment of cancer. The short answer is, potentially a great deal. By any definition, it is ‘disruptive technology’ that has the potential to change the face of cancer therapy. […]

Read More

CEO Blog : Nyrada,Inc. is launched

Posted on February 19th, 2018 by Blog Author

It’s been 9 months in the making, and a good deal of hard work, but finally our US subsidiary, Nyrada, Inc. is launched with the successful closing of a $4M capital raise. What does Nyrada mean to me as a NOX shareholder? As a NOX shareholder, through NOX, you now have a ‘stake’ in a […]

Read More

Kazia Therapeutics Agreement and Intellectual Property

Posted on January 22nd, 2018 by Blog Author

In response to shareholder enquiry, this is a clarifying note about the agreement recently entered into between NOX and KZA. The agreement represents a commercial decision reached by both parties that provides NOX with the certainty it needs as it prepares to enter a Phase 2/Phase 3 clinical program for its lead drug candidate, NOX66. […]

Read More

CEO Blog: The Patent Application Process Explained

Posted on December 4th, 2017 by Blog Author

  The two key tests in being awarded a patent over any intellectual property (IP) are novelty and inventiveness. In the drug development world, proving both is much easier where there is no pre-existing IP…. For example, no-one had described the new molecule before (known as a New Chemical Entity), so it is novel; or […]

Read More

CEO Blog: comment on clinical data released at ESMO 2017 Congress

Posted on September 21st, 2017 by Blog Author

A short note on the clinical data we presented at ESMO. This is early data from our first-in-human clinical study, so it is important to keep that perspective. Over the course of the next 6 months we plan on reporting on this and other clinical studies at various international and local oncology conferences. Progressively, the […]

Read More

CEO Blog explains Noxopharm Brain Cancer Announcement 29 August 2017

Posted on September 3rd, 2017 by Blog Author

Is it possible that Noxopharm can do something meaningful for patients with brain cancer, where so many others have failed? We believe so, with our recent announcement going some way to justifying that belief. Yes, what we have just announced is laboratory data. And, yes, we have a long way to go before we can […]

Read More

St. Vincent’s Hospital, Sydney study explained

Posted on June 9th, 2017 by Blog Author

Unless you have had prostate cancer, or graduated in medicine, or hold a PhD in physics, chances are you have never heard of the terms radiotherapy brachytherapy and 177-lutetium-PSMA peptide complex. So here goes with an explanation…an easy one first and then a more in-depth explanation if you are up to it. Simple explanation: a […]

Read More

March 2017 Quarter Appendix- 4C Follow Up : CEO Blog

Posted on April 29th, 2017 by Blog Author

The following are some questions generated by last Thursday’s announcement. Q: Why are we planning on running 7 clinical studies? A: Because we want to be in a Phase 3 registration study in 2019, and that means knowing by the end of 2018 what that study will look like. We also want that Phase 3 […]

Read More

Idronoxil and urogenital cancers. Noxopharm CEO Blog March 2017

Posted on March 30th, 2017 by Blog Author

Our last announcement (27th March) reported on two developments. Both relating to some research being done under contract for Noxopharm by Monash University and partially funded by the Federal Government. First development:   idronoxil-C  Q. What is idronoxil-C? A.  Idronoxil-C is an exciting development that we believe has increased very considerably the value of the Company’s […]

Read More